Liminal BioSciences Net Income 2015-2021 | LMNL

Liminal BioSciences net income from 2015 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Liminal BioSciences Annual Net Income
(Millions of US $)
2020 $-88
2019 $-155
2018 $-151
2017 $-85
2016 $-76
2015 $-40
2014 $2
Liminal BioSciences Quarterly Net Income
(Millions of US $)
2021-06-30 $-26
2021-03-31 $-16
2020-12-31 $-30
2020-09-30 $-17
2020-06-30 $-20
2020-03-31 $-21
2019-12-31 $-12
2019-09-30 $-22
2019-06-30 $-100
2019-03-31 $-21
2018-12-31 $-79
2018-09-30 $-22
2018-06-30 $-25
2018-03-31 $-25
2017-12-31 $-30
2017-09-30 $-12
2017-06-30 $-22
2017-03-31 $-20
2016-12-31 $-28
2016-09-30 $-20
2016-06-30 $-17
2016-03-31 $-11
2015-12-31 $-8
2015-09-30 $-7
2015-06-30 $-10
2015-03-31 $-16
2014-12-31 $7
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.057B $0.002B
Liminal BioSciences Inc. is a biotechnology company. It engages in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. The company's product pipeline consists of PBI-4050, which are in clinical stage. Liminal BioSciences Inc., formerly known as Prometic Life Sciences Inc., is based in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48